News

PH raises risk of severe cardiac, respiratory issues in HIV patients

Having pulmonary hypertension (PH) worsens the likelihood of potentially life-threatening cardiac and respiratory complications in people with human immunodeficiency virus (HIV) infection, a U.S. database study reported. Its findings “can inform clinical practice and help healthcare providers make more informed decisions regarding the screening, diagnosis, and management of PH…

Trial enrollment begins to test long-acting relaxin formula in PH-HFpEF

Enrollment has begun in a Phase 1b study of Tectonic Therapeutic’s TX45, an investigational treatment for people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). TX45 is a long-acting formulation of relaxin, a protein involved in reproduction and cardiovascular function. It has anti-fibrotic, or anti-scarring,…

FDA approves sotatercept, now Winrevair, to treat PAH in adults

The U.S. Food and Drug Administration (FDA) has approved the under-the-skin injection therapy sotatercept-csrk — to be marketed under the brand name Winrevair — to treat adults with pulmonary arterial hypertension (PAH). The now-approved treatment is expected to be available for dispensing by select U.S. specialty pharmacies by the…

FDA approves Opsynvi as 1st single-tablet PAH combo treatment

The U.S. Food and Drug Administration (FDA) has approved once-daily, fixed-dose tablets containing a combination of macitentan and tadalafil — to be marketed under the brand name Opsynvi — to treat adults with pulmonary arterial hypertension (PAH). The approval marks the first single-tablet treatment combination to become available…

MicroRNA levels may help predict CTEPH diagnosis: Study

Blood levels of microRNA — small RNA molecules that regulate protein production — are decreased in people with pulmonary embolism (PE) compared with healthy people. PE is the cause of chronic thromboembolic pulmonary hypertension (CTEPH). However, higher blood levels of miR-let7a were found in people with acute PE who…

Men with PAH have higher mortality, despite better measures

Despite having more favorable clinical measures, such as blood flow, men with pulmonary arterial hypertension (PAH) have a higher mortality risk than women with the disease, according to a recent study. This is known as the “sex paradox” and may occur because men may develop PAH only if higher…

IPAH disease worsening linked to 2 tumor biomarkers: Study

Elevated levels of two tumor biomarkers, AFP and CA125, were found to predict disease worsening in people with idiopathic pulmonary arterial hypertension (IPAH) in a new study from China. “Changes in AFP over time serve as an indicator of disease alteration, enabling detection of disease progression or treatment response,”…

Delayed diagnosis common with PAH, multinational survey finds

About 41% of pulmonary arterial hypertension (PAH) patients in a multinational survey were initially misdiagnosed, seeing an average of 2.9 physicians before getting their correct diagnosis. The non-specific nature of their disease symptoms and a lack of awareness among patients and primary care physicians contribute to this delay,…


A Conversation With Rare Disease Advocates